Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation

Clinical Genetics

Volumn 52, Issue 6, 1997, Pages 416-421

  Fagerlund, T H ^a   Ording H ^b   Bendixen, D ^b   Islander, G ^c   Ranklev Twetman, E ^c   Berg, K ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Discordance; DNA; Genetics; Malignant hyperthermia (MH); MH susceptibility; Mutations; RYR1

Indexed keywords

RYANODINE RECEPTOR;

ARTICLE; CLINICAL ARTICLE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; MALIGNANT HYPERTHERMIA; PRIORITY JOURNAL; SCANDINAVIA;

EID: 0031407060     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.1997.tb02561.x     Document Type: Article

References (21)

1. Deufel T, Sudbrak R, Feist Y, Rubsam B, Du Chesne I, Schäfer KL, Röwer N, Grimm T, Lehmann-Horn F, Hartung EJ, Müller CR. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am J Hum Genet 1995: 56: 1334-1342.
2. Eikelenboom G, Minkema D. Prediction of PSE with a non-lethal test for the halothane-induced porcine MH syndrome. Neth J Vet Sci 1974: 99: 421-426.
3. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984: 56: 1267-1269.
4. European Malignant Hyperpyrexia Group. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). Br J Anaesth 1985: 57: 1038.
5. Fagerlund T, Ørding H, Bendixen D, Berg K. Search for three known mutations in the RYR1 gene in 48 Danish families with malignant hyperthermia. Clin Genet 1994: 46: 401-404.
6. Fagerlund TH, Islander G, Twetman ER, Berg K. A search for three known RYR1 gene mutations in 41 Swedish families with predisposition to malignant hyperthermia. Clin Genet 1995: 48: 12-16.
7. Fagerlund T, Ørding H, Bendixen D, Islander G, Ranklev-Twetman E, Berg K. RYR1 mutation G1021A (Gly341Arg)-is not frequent in Danish and Swedish families with malignant hyperthermia susceptibility. Clin Genet 1996: 49: 186-188.
8. Fletcher JE, Calvo PA, Rosenberg H. Phenotypes associated with malignant hyperthermia susceptibility in swine genotyped as homozygous or heterozygous for the ryanodine receptor mutation. Br J Anaesth 1993: 71: 410-417.
9. Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemizi J, Britt BA, Duff CL, Worton RG, MacLennan DH. A substitution of Cysteine for Arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991: 11: 751-755.
10. Healy JMS, Quane KA, Keating KE, Lehane M, Heffron JJA, McCarthy TV. Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree. J Med Genet 1996: 33: 18-24.
11. Iles DE, Segers B, de Jong P, Alleman J, Wieringa B. Dinucleotide repeat polymorphism at the D19S191 locus. Nucleic Acids Res 1992: 20: 1170.
12. Iles DE, Lehmann-Horn F, Scherer SW, Tsui L-C, Olde Weghuis D, Suijkerbuijk R, F Heytens L, Mikala G, Schwartz A, Ellis FR, Stewart AD, Deufel T, Wieringa B. Localisation of the gene encoding the alpha-2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 1994: 3: 969-975.
13. Islander G, Bendixen D, Ranklev-Twetman E, Ørding H. Results of in-vitro contracture testing of both parents of malignant hyperthermia susceptible probands. Acta Anaesthesiol Scand 1996: 40: 579-584.
14. Larach MG, for The North American Malignant Hyperthermia Group. Anesth Analg 1989: 69: 511-515.
15. Levitt RC, Jedlicka AE, Nouri N. Dinucleotide repeat polymorphism at the hormone sensitive lipase (LIPE) locus. Hum Mol Genet 1992a: 1: 2: 139.
16. Levitt RC, Olckers A, Meyers S, Levitt MK, Rosenberg H, Fletcher JE, Isaacs H, Meyers DA. Evidence for the localization of a malignant hyperthermia susceptibility locus to human chromosome 17q. Genomics 1992b: 14: 562-566.
17. Quane KA, Healy JMS, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ørding H, Bendixen D, Mortier W, Linz U, Müller C, McCarthy TV. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993: 5: 51-55.
18. Quane KA, Keating KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA, Lehane M, Heytens L, Krivosic, Horbert R, Adnet P, Ellis FR, Monnier N, Lunardi J, McCarthy TV. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implication for diagnosis and heterogeneity studies. Hum Mol Genet 1994: 3: 471-476.
19. Sudbrak R, Procaccio V, Klausnitzer M, Curran JL, Monsieurs K, Van Broeckhoven C, Ellis R, Heyetens L, Hartung EJ, Kozak-Ribbens G, Heilinger D, Weissenbach J, Lehman-Horn F, Müller CR, Deufel T, Stewart AD, Lunardi J. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet 1995: 56: 684-691.
20. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989: 44: 3: 388-396.
21. Zhang Y, Chen HS, Khanna VK, de Leon S, Phillips MS, Schappert K, Britt BA, Brownell AKW, MacLennan DH. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993: 5: 46-50.